JacobP.LaubachMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor, Harvard Medical School

Join to view full profile

Dr. Laubach is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Laubach's full profile

Already have an account?

Office
44 Binney St
# D1B30
Boston, MA 02115
Phone+1 617-632-2127

Fax+1 617-632-6624

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
Duke University HospitalResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999

Certifications & Licensure

MA State Medical License 2008 - 2025
NH State Medical License 2023 - 2025
NC State Medical License 1999 - 2009
American Board of Internal Medicine Hematology

Clinical Trials

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro Start of enrollment: 2010 Oct 01
Completed
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 May 01
Active, not recruiting
Phase 1
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease Start of enrollment: 2012 Jun 01
Completed
Phase 1
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2013 May 01
Completed
Phase 1
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma Start of enrollment: 2013 Oct 01
Completed
Not Applicable
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 1
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jun 05
Completed
Phase 1
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Start of enrollment: 2015 Dec 01
Active, not recruiting
Phase 2
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma Start of enrollment: 2016 Jun 21
Active, not recruiting
Phase 2
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM Start of enrollment: 2020 Oct 21
Active, not recruiting
Phase 2
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency Start of enrollment: 2016 Aug 01
Recruiting
Phase 2
Roles: Contact
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM Start of enrollment: 2021 Jul 13
Recruiting
Phase 2
Roles: Principal Investigator, Contact, Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2024-12-03
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2024-10-25
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves
American Journal of Hematology. 2024-07-01

Abstracts/Posters

Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refr...
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Debate: Should Everyone Receive Monoclonal Antibodies in First Relapse? Yes
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

GRIFFIN: Daratumumab Combination Maintains Deep Durable Response in Transplant-Eligible MyelomaDecember 13th, 2021
(Daratumumab) in Patients with Newly Diagnosed Multiple MyelomaDecember 11th, 2021
Treatment Trio Soars in New Transplant-Ineligible MMNovember 18th, 2021
Join now to see all